High blood pressure is one of the most common health problems in the world. Millions of people live with it, and many may not even realize they have it because it often causes no clear symptoms.
Doctors sometimes call high blood pressure a “silent killer” because it can quietly damage the body for years before serious problems appear.
When blood pressure stays too high for a long time, it puts extra strain on the heart and blood vessels. Over time, this can lead to dangerous health conditions such as heart attacks, strokes, kidney disease, and even early death. Because of these risks, controlling blood pressure is very important for long‑term health.
Today, the most common way to treat high blood pressure is through daily medication. Many patients take pills that help relax blood vessels, reduce fluid in the body, or slow the heart rate. These medicines can be very effective.
However, one major problem is that many people forget to take their medication regularly. Some people skip doses, while others stop taking their medicine altogether when they start feeling better.
When medication is not taken consistently, blood pressure may rise again. This makes it harder for doctors to keep the condition under control. Because of this challenge, scientists are searching for new treatments that are easier for patients to follow.
One promising new treatment is a drug called zilebesiran. Researchers from several institutions, including scientists at the University of Edinburgh, have been studying this medication. Early results from clinical tests suggest that the drug may help lower blood pressure for a long time after only one injection.
In the study, researchers tested zilebesiran in people who already had high blood pressure. The results showed that a single injection of the drug could reduce blood pressure for up to six months. This means patients might only need treatment twice a year instead of remembering to take pills every day.
The researchers measured a number called systolic blood pressure. This is the top number in a blood pressure reading and represents the pressure in the arteries when the heart beats and pushes blood through the body. Lowering this number can greatly reduce the risk of heart disease and stroke.
In the clinical trial, different doses of zilebesiran were tested. A 200‑milligram dose lowered systolic blood pressure by more than 10 millimeters of mercury, which doctors write as mmHg.
A larger dose of 800 milligrams lowered systolic blood pressure by more than 20 mmHg. Reductions of this size are considered very meaningful because they can move patients from a dangerous range into a safer one.
The drug was developed by a biotechnology company in the United States called Alnylam. What makes zilebesiran different from traditional blood pressure medicines is the way it works inside the body.
Most blood pressure medications act on the blood vessels directly or affect hormones after they are already produced. Zilebesiran takes a different approach. It works earlier in the process by stopping the body from producing a hormone that raises blood pressure.
This hormone is called angiotensin. Angiotensin tightens blood vessels and makes blood pressure rise. Zilebesiran blocks the production of a protein called angiotensinogen in the liver. This protein is necessary for the body to make angiotensin.
By stopping angiotensinogen from being produced, the drug reduces the amount of angiotensin in the body and helps keep blood vessels more relaxed.
The study included 107 adults with high blood pressure. Among them, 80 people received a single injection of zilebesiran, while the remaining participants received a placebo. A placebo is a treatment that looks like the real medicine but does not contain any active drug. Scientists use placebos to help determine whether the medication itself is responsible for the results.
The early findings were encouraging, but researchers emphasize that more studies are still needed. Larger clinical trials will be required to confirm that the drug is safe and effective over longer periods of time.
Professor David Webb from the University of Edinburgh, one of the researchers involved in the study, described the drug as a potentially important advance in the treatment of high blood pressure. He noted that it has been about 17 years since a completely new type of blood pressure medication became available.
A treatment that only needs to be given once every six months could make it much easier for patients to stay on track with their therapy. This could lead to better blood pressure control and reduce the risk of serious cardiovascular diseases.
Before zilebesiran can be widely used, it must go through additional testing and regulatory review. These steps are necessary to ensure that the treatment is both safe and effective for large numbers of patients.
If future studies confirm the early results, this new injection could become a simple and reliable option for managing high blood pressure. Instead of remembering daily pills, patients might only need two injections each year to help keep their blood pressure under control and protect their long‑term health.
If you care about high blood pressure, please read studies that early time-restricted eating could help improve blood pressure, and natural coconut sugar could help reduce blood pressure and artery stiffness.
For more information about blood pressure, please see recent studies about How to eat your way to healthy blood pressure and results showing that Modified traditional Chinese cuisine can lower blood pressure.
Copyright © 2026 Knowridge Science Report. All rights reserved.
